Stevanato Group S.p.A. (STVN) shares plummeted 5.16% in intraday trading on Tuesday, despite the company reporting better-than-expected second-quarter results. The sharp decline suggests that investors may be focusing on the company's outlook, which appears to have fallen short of market expectations.

The Italian-based medical technology company reported Q2 2025 revenue of €280.0 million, surpassing analysts' estimates of €268.3 million. Net income came in at €29.7 million, also beating the expected €29.2 million. The company's earnings per share (EPS) of €0.11 met consensus estimates.

However, Stevanato's forward guidance seems to have dampened investor enthusiasm. The company forecasts full-year revenue between €1,160 million and €1,190 million, with adjusted EBITDA ranging from €288.5 million to €301.8 million. The projected adjusted EPS for the fiscal year is set at €0.50 to €0.54. These figures, while showing growth, may not have met the market's more optimistic expectations, potentially explaining the stock's significant drop despite the earnings beat.